These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 11992050)
1. Hereditary prostate cancer: clinical characteristics and survival. Bratt O; Damber JE; Emanuelsson M; Grönberg H J Urol; 2002 Jun; 167(6):2423-6. PubMed ID: 11992050 [TBL] [Abstract][Full Text] [Related]
2. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Grönberg H; Damber L; Jonson H; Damber JE Urology; 1997 Mar; 49(3):374-8. PubMed ID: 9123701 [TBL] [Abstract][Full Text] [Related]
3. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. Siddiqui SA; Sengupta S; Slezak JM; Bergstralh EJ; Zincke H; Blute ML J Urol; 2006 Sep; 176(3):1118-21. PubMed ID: 16890705 [TBL] [Abstract][Full Text] [Related]
5. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379 [TBL] [Abstract][Full Text] [Related]
7. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E; Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057 [TBL] [Abstract][Full Text] [Related]
8. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765 [TBL] [Abstract][Full Text] [Related]
9. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer progression and survival in BRCA2 mutation carriers. Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157 [TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985 [TBL] [Abstract][Full Text] [Related]
12. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. Graff JN; Mori M; Li H; Garzotto M; Penson D; Potosky AL; Beer TM J Urol; 2007 Apr; 177(4):1307-12. PubMed ID: 17382720 [TBL] [Abstract][Full Text] [Related]
13. Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer? Karlsson CT; Malmer B; Wiklund F; Grönberg H J Urol; 2006 Aug; 176(2):538-43. PubMed ID: 16813884 [TBL] [Abstract][Full Text] [Related]
14. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Beyer DC; McKeough T; Thomas T Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331 [TBL] [Abstract][Full Text] [Related]
15. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Ryan CJ; Elkin EP; Cowan J; Carroll PR Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446 [TBL] [Abstract][Full Text] [Related]
16. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort. Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416 [TBL] [Abstract][Full Text] [Related]
18. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764 [TBL] [Abstract][Full Text] [Related]
19. [Characterisation of families with hereditary prostate cancer in the Netherlands]. Meulenbeld HJ; Verhage BA; Kil PJ; Kiemeney LA; Vasen HF Ned Tijdschr Geneeskd; 2002 Oct; 146(41):1938-42. PubMed ID: 12404910 [TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]